CY1725A - Combination dosage form for pre-menopausal women - Google Patents

Combination dosage form for pre-menopausal women Download PDF

Info

Publication number: CY1725A
Authority: CY; Cyprus
Prior art keywords: estradiol; levonorgestrel; days; dosage form; desogestrel
Prior art date: 1986-07-15

Application number

CY172594A

Other languages

English (en)

Original Assignee

American Home Prod

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1986-07-15

Filing date

1994-05-06

Publication date

1994-05-06

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25388101&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1725(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1994-05-06 Application filed by American Home Prod filed Critical American Home Prod

1994-05-06 Publication of CY1725A publication Critical patent/CY1725A/en

Links

239000002552 dosage form Substances 0.000 title claims abstract description 53
WWYNJERNGUHSAO-XUDSTZEESA-N (+)-Norgestrel Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 WWYNJERNGUHSAO-XUDSTZEESA-N 0.000 claims abstract description 43
229960004400 levonorgestrel Drugs 0.000 claims abstract description 43
229960005309 estradiol Drugs 0.000 claims abstract description 35
229940011871 estrogen Drugs 0.000 claims abstract description 26
239000000262 estrogen Substances 0.000 claims abstract description 26
239000000583 progesterone congener Substances 0.000 claims abstract description 26
SIGSPDASOTUPFS-XUDSTZEESA-N gestodene Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](CC)([C@](C=C4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 SIGSPDASOTUPFS-XUDSTZEESA-N 0.000 claims abstract description 24
229960005352 gestodene Drugs 0.000 claims abstract description 24
239000006187 pill Substances 0.000 claims abstract description 24
229960004976 desogestrel Drugs 0.000 claims abstract description 23
RPLCPCMSCLEKRS-BPIQYHPVSA-N desogestrel Chemical compound C1CC[C@@H]2[C@H]3C(=C)C[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 RPLCPCMSCLEKRS-BPIQYHPVSA-N 0.000 claims abstract description 23
GCKFUYQCUCGESZ-BPIQYHPVSA-N etonogestrel Chemical compound O=C1CC[C@@H]2[C@H]3C(=C)C[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 GCKFUYQCUCGESZ-BPIQYHPVSA-N 0.000 claims abstract description 22
230000027758 ovulation cycle Effects 0.000 claims abstract description 22
IMSSROKUHAOUJS-MJCUULBUSA-N mestranol Chemical compound C1C[C@]2(C)[C@@](C#C)(O)CC[C@H]2[C@@H]2CCC3=CC(OC)=CC=C3[C@H]21 IMSSROKUHAOUJS-MJCUULBUSA-N 0.000 claims abstract description 21
229960001390 mestranol Drugs 0.000 claims abstract description 21
BFPYWIDHMRZLRN-UHFFFAOYSA-N 17alpha-ethynyl estradiol Natural products OC1=CC=C2C3CCC(C)(C(CC4)(O)C#C)C4C3CCC2=C1 BFPYWIDHMRZLRN-UHFFFAOYSA-N 0.000 claims abstract description 20
BFPYWIDHMRZLRN-SLHNCBLASA-N Ethinyl estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 claims abstract description 20
229960002568 ethinylestradiol Drugs 0.000 claims abstract description 20
VIKNJXKGJWUCNN-XGXHKTLJSA-N norethisterone Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 VIKNJXKGJWUCNN-XGXHKTLJSA-N 0.000 claims abstract description 16
229940053934 norethindrone Drugs 0.000 claims abstract description 15
230000003054 hormonal effect Effects 0.000 claims abstract description 11
238000009256 replacement therapy Methods 0.000 claims abstract description 9
VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 claims abstract description 8
239000000203 mixture Substances 0.000 claims description 5
229930182833 estradiol Natural products 0.000 claims description 4
238000004519 manufacturing process Methods 0.000 claims description 2
238000000034 method Methods 0.000 abstract description 3
239000003433 contraceptive agent Substances 0.000 description 5
230000002254 contraceptive effect Effects 0.000 description 5
230000002503 metabolic effect Effects 0.000 description 4
238000002560 therapeutic procedure Methods 0.000 description 4
206010014733 Endometrial cancer Diseases 0.000 description 3
206010014759 Endometrial neoplasm Diseases 0.000 description 3
230000000694 effects Effects 0.000 description 3
229940127234 oral contraceptive Drugs 0.000 description 3
239000003539 oral contraceptive agent Substances 0.000 description 3
239000000126 substance Substances 0.000 description 3
239000003826 tablet Substances 0.000 description 3
RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
230000002411 adverse Effects 0.000 description 2
230000032683 aging Effects 0.000 description 2
239000007894 caplet Substances 0.000 description 2
239000002775 capsule Substances 0.000 description 2
150000001875 compounds Chemical class 0.000 description 2
230000018109 developmental process Effects 0.000 description 2
125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 2
238000009472 formulation Methods 0.000 description 2
229940088597 hormone Drugs 0.000 description 2
239000005556 hormone Substances 0.000 description 2
238000001794 hormone therapy Methods 0.000 description 2
150000002632 lipids Chemical class 0.000 description 2
230000009245 menopause Effects 0.000 description 2
230000002265 prevention Effects 0.000 description 2
229940095055 progestogen systemic hormonal contraceptives Drugs 0.000 description 2
208000024891 symptom Diseases 0.000 description 2
WFHDOIKSUKQTLH-IBXXTFBESA-N (8r,9s,10r,13s,14s,17r)-13-ethyl-17-ethynyl-17-hydroxy-1,2,6,7,8,9,10,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-3-one;[(8r,9s,13s,14s,17s)-3-hydroxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-17-yl] pentanoate Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1.C1CC2=CC(O)=CC=C2[C@@H]2[C@@H]1[C@@H]1CC[C@H](OC(=O)CCCC)[C@@]1(C)CC2 WFHDOIKSUKQTLH-IBXXTFBESA-N 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
206010002659 Anovulatory cycle Diseases 0.000 description 1
206010003439 Artificial menopause Diseases 0.000 description 1
206010006187 Breast cancer Diseases 0.000 description 1
208000026310 Breast neoplasm Diseases 0.000 description 1
RSEPBGGWRJCQGY-RBRWEJTLSA-N Estradiol valerate Chemical compound C1CC2=CC(O)=CC=C2[C@@H]2[C@@H]1[C@@H]1CC[C@H](OC(=O)CCCC)[C@@]1(C)CC2 RSEPBGGWRJCQGY-RBRWEJTLSA-N 0.000 description 1
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
206010060800 Hot flush Diseases 0.000 description 1
206010020772 Hypertension Diseases 0.000 description 1
206010022998 Irritability Diseases 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
IMONTRJLAWHYGT-ZCPXKWAGSA-N Norethindrone Acetate Chemical compound C1CC2=CC(=O)CC[C@@H]2[C@@H]2[C@@H]1[C@@H]1CC[C@](C#C)(OC(=O)C)[C@@]1(C)CC2 IMONTRJLAWHYGT-ZCPXKWAGSA-N 0.000 description 1
208000001132 Osteoporosis Diseases 0.000 description 1
208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
230000001548 androgenic effect Effects 0.000 description 1
230000002513 anti-ovulatory effect Effects 0.000 description 1
239000004019 antithrombin Substances 0.000 description 1
238000003556 assay Methods 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
230000035606 childbirth Effects 0.000 description 1
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 1
208000029078 coronary artery disease Diseases 0.000 description 1
-1 deogestrel Chemical compound 0.000 description 1
150000002009 diols Chemical class 0.000 description 1
230000002357 endometrial effect Effects 0.000 description 1
239000003687 estradiol congener Substances 0.000 description 1
229960004766 estradiol valerate Drugs 0.000 description 1
238000009164 estrogen replacement therapy Methods 0.000 description 1
230000001076 estrogenic effect Effects 0.000 description 1
230000035558 fertility Effects 0.000 description 1
229940125697 hormonal agent Drugs 0.000 description 1
125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
206010022437 insomnia Diseases 0.000 description 1
230000003821 menstrual periods Effects 0.000 description 1
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 1
229960004719 nandrolone Drugs 0.000 description 1
230000017570 negative regulation of blood coagulation Effects 0.000 description 1
229960001652 norethindrone acetate Drugs 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
230000000624 ovulatory effect Effects 0.000 description 1
239000011087 paperboard Substances 0.000 description 1
230000001766 physiological effect Effects 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
230000000757 progestagenic effect Effects 0.000 description 1
230000001072 progestational effect Effects 0.000 description 1
239000000186 progesterone Substances 0.000 description 1
229960003387 progesterone Drugs 0.000 description 1
230000001681 protective effect Effects 0.000 description 1
230000001850 reproductive effect Effects 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Reproductive Health (AREA)
Endocrinology (AREA)
Urology & Nephrology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines Containing Plant Substances (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Steroid Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)

CY172594A 1986-07-15 1994-05-06 Combination dosage form for pre-menopausal women CY1725A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US88597186A	1986-07-15	1986-07-15

Publications (1)

Publication Number	Publication Date
CY1725A true CY1725A (en)	1994-05-06

Family

ID=25388101

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CY172594A CY1725A (en)	1986-07-15	1994-05-06	Combination dosage form for pre-menopausal women

Country Status (20)

Country	Link
EP (1)	EP0253607B2 (fr)
JP (1)	JP2645510B2 (fr)
KR (1)	KR960001371B1 (fr)
AT (1)	ATE75401T1 (fr)
AU (1)	AU597084B2 (fr)
CY (1)	CY1725A (fr)
DE (1)	DE3778599D1 (fr)
DK (2)	DK174724B1 (fr)
ES (1)	ES2033850T5 (fr)
GB (1)	GB2192542B (fr)
GR (1)	GR3004472T3 (fr)
HK (1)	HK67393A (fr)
IE (1)	IE61236B1 (fr)
LU (1)	LU90634I2 (fr)
NL (1)	NL300025I2 (fr)
PH (1)	PH25944A (fr)
PT (1)	PT85305B (fr)
SG (1)	SG55093G (fr)
WO (1)	WO1988000469A1 (fr)
ZA (1)	ZA875010B (fr)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4816258A (en) *	1987-02-26	1989-03-28	Alza Corporation	Transdermal contraceptive formulations
CH674618A5 (fr) *	1987-04-02	1990-06-29	Ciba Geigy Ag
DE3864210D1 (de) *	1987-07-06	1991-09-19	Akzo Nv	Pharmazeutische dosierungseinheit zur vorbeugung bzw. behandlung von klimakterischen beschwerden.
AU630334B2 (en) *	1987-09-24	1992-10-29	Jencap Research Ltd.	Hormone preparations for hormone replacement therapy and contraceptive method
US5276022A (en) *	1987-09-24	1994-01-04	Jencap Research Ltd.	Hormone preparation and method
DE3916112A1 (de) *	1989-05-16	1990-11-22	Schering Ag	Dihydrospirorenon als antiandrogen
US5043331A (en) *	1989-06-15	1991-08-27	Orion-Yhtyma Oy	Treatment of postmenopausal disorders
IE71203B1 (en) *	1990-12-13	1997-02-12	Akzo Nv	Low estrogen oral contraceptives
IE62665B1 (en) *	1990-12-17	1995-02-22	Akzo Nv	Contraceptive regimen
US7704983B1 (en)	1992-03-02	2010-04-27	Eastern Virginia Medical School	Antiprogestin method for reducing side effects associated with low dosage HRT and oral contraception
MX9301121A (es) *	1992-03-02	1993-09-01	Schering Ag	Metodo y equipo para la contracepcion oral y regulacion de la menstruacion con estrogeno/progestina/aniprogestina.
RU2119337C1 (ru) *	1992-03-21	1998-09-27	Энтек Гезельшафт фюр Эндокринологише Технологи мбХ	Трансдермальный препарат продленного действия с антиостеопоротической активностью
DE4227989A1 (de) *	1992-08-21	1994-06-09	Schering Ag	Mittel zur transdermalen Applikation enthaltend 3-Keto-desogestrel
US6407082B1 (en)	1996-09-13	2002-06-18	New Life Pharmaceuticals Inc.	Prevention of ovarian cancer by administration of a vitamin D compound
DE4344462C2 (de)	1993-12-22	1996-02-01	Schering Ag	Zusammensetzung für die Empfängnisverhütung
DE4411585A1 (de) *	1994-03-30	1995-10-05	Schering Ag	Pharmazeutisches Kombinationspräparat zur hormonalen Kontrazeption
US5552394A (en) *	1994-07-22	1996-09-03	The Medical College Of Hampton Roads	Low dose oral contraceptives with less breakthrough bleeding and sustained efficacy
US5922349A (en) *	1995-09-28	1999-07-13	Schering Aktiengesellschaft	Hormone replacement therapy method and hormone dispenser
US5747480A (en) *	1996-05-08	1998-05-05	American Home Products Corporation	Oral contraceptive
US5888543A (en) *	1996-07-26	1999-03-30	American Home Products Corporation	Oral contraceptives
US5858405A (en) *	1996-07-26	1999-01-12	American Home Products Corporation	Oral contraceptive
KR100518102B1 (ko) *	1996-07-26	2005-10-04	와이어쓰	프로게스틴과 에스트로겐의 혼합물을 포함하는 단일상 피임약 키트
US6479475B1 (en)	1996-07-26	2002-11-12	Wyeth	Oral contraceptive
US6451778B1 (en)	1996-07-26	2002-09-17	Wyeth	Oral contraceptive
US6511970B1 (en)	1996-09-13	2003-01-28	New Life Pharmaceuticals Inc.	Prevention of ovarian cancer by administration of products that induce transforming growth factor-beta and/or apoptosis in the ovarian epithelium
US6765002B2 (en)	2000-03-21	2004-07-20	Gustavo Rodriguez	Prevention of ovarian cancer by administration of products that induce transforming growth factor-β and/or apoptosis in the ovarian epithelium
US6034074A (en)	1996-09-13	2000-03-07	New Life Pharmaceuticals Inc.	Prevention of ovarian cancer by administration of a Vitamin D compound
US6028064A (en)	1996-09-13	2000-02-22	New Life Pharmaceuticals Inc.	Prevention of ovarian cancer by administration of progestin products
FR2754179B1 (fr)	1996-10-08	1998-12-24	Theramex	Nouvelle composition hormononale et son utilisation
WO2001030355A1 (fr)	1999-10-25	2001-05-03	Laboratoire Theramex	Medicament contraceptif a base d'un progestatif et d'un estrogene et son mode de preparation
US5898032A (en) *	1997-06-23	1999-04-27	Medical College Of Hampton Roads	Ultra low dose oral contraceptives with less menstrual bleeding and sustained efficacy
JP2001513566A (ja) *	1997-08-27	2001-09-04	オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド	経口避妊における、エストロゲンと子宮内膜節約性プロゲスチンおよび子宮内膜萎縮性プロゲスチンとの組み合わせ物
US6787531B1 (en)	1999-08-31	2004-09-07	Schering Ag	Pharmaceutical composition for use as a contraceptive
US20020132801A1 (en) *	2001-01-11	2002-09-19	Schering Aktiengesellschaft	Drospirenone for hormone replacement therapy
FR2832065B1 (fr) *	2001-11-13	2004-11-05	Besins Int Belgique	Composition pharmaceutique a base de progesterone micronisee son procede de preparation et ses utilisations
NZ591627A (en)	2001-12-05	2012-09-28	Teva Womens Health Inc	Oral contraceptives to prevent pregnancy and diminish premenstrual symptomatology
EP1624848A4 (fr)	2003-05-02	2009-02-25	Duramed Pharmaceuticals Inc	Methodes de traitement hormonal faisant appel a des schemas contraceptifs a cycle prolonge
NZ545130A (en)	2003-07-16	2009-03-31	Duramed Pharmaceuticals Inc	Methods of hormonal treatment utilizing contraceptive regimens with continuous estrogen administration
ATE410171T1 (de)	2003-11-14	2008-10-15	Warner Chilcott Co Inc	Graduierte östrogen-kontrazeptiva
EP1535618A1 (fr)	2003-11-26	2005-06-01	Schering Aktiengesellschaft	Préparation pharmaceutique pour le traitement hormonal continuel sur plus de 21-28 jours comprenant deux compositions d'estrogène et/ou de progestine
DE102004019743B4 (de)	2004-04-20	2008-11-27	Bayer Schering Pharma Aktiengesellschaft	Mehrphasenpräparat zur Kontrazeption auf der Basis eines natürlichen Estrogens
DE102004026679A1 (de)	2004-05-28	2005-12-15	Grünenthal GmbH	Hormonales Kontrazeptivum enthaltend eine Kombination aus Ethinylestradiol und Chlormadinonacetat
DE102004026670A1 (de)	2004-05-28	2005-12-15	Grünenthal GmbH	Hormonales Kontrazeptivum enthaltend eine Kombination aus Ethinylestradiol und Chlormadinonacetat
DE102004026671A1 (de)	2004-05-28	2005-12-15	Grünenthal GmbH	Darreichungsform zur hormonalen Kontrazeption
US20070111975A1 (en)	2004-10-07	2007-05-17	Duramed Pharmaceuticals, Inc.	Methods of Hormonal Treatment Utilizing Ascending-Dose Extended Cycle Regimens
MX2007004120A (es)	2004-10-07	2007-06-15	Duramed Pharmaceuticals Inc	Metodos de tratamiento hormonal utilizando regimentes de ciclo prolongado de dosis ascendente.
UY29527A1 (es) *	2005-05-13	2006-12-29	Schering Ag	Composicinn farmaccutica que contienen gestrgenos y/o estrngenos y 5-metil - (6s) - tetrhidrofolato.
US8153616B2 (en)	2005-10-17	2012-04-10	Bayer Pharma Aktiengesellschaft	Combination preparation for oral contraception and oral therapy of dysfunctional uterine bleeding containing estradiol valerate and dienogest and method of using same
WO2007076144A2 (fr)	2005-12-27	2007-07-05	Duramed Pharmaceuticals, Inc.	Compositions d'œstrogènes conjugués, applicateurs, kits et procédés pour les préparer et les utiliser
US8617597B2 (en)	2006-07-06	2013-12-31	Bayer Intellectual Property Gmbh	Pharmaceutical composition containing a tetrahydrofolic acid
EP1930010A1 (fr)	2006-10-20	2008-06-11	Bayer Schering Pharma Aktiengesellschaft	Utilisation de valvérate d'estradiol ou de 17ß-estradiol combiné à du dienogest pour traiter par voie orale la récupération et/ou l'augmentation de la libido féminine
TW200840595A (en) *	2006-12-12	2008-10-16	Organon Nv	Oral contraceptive spray
AU2007338843B2 (en) *	2006-12-20	2013-05-09	Teva Women's Health, Inc.	Orally disintegrating solid dosage forms comprising progestin and methods of making and use thereof
BRPI0819571A2 (pt)	2007-12-20	2019-09-24	Teva Womenss Health Inc	"método para contracepção de emergência, pacote farmacêutico para contracepção de emergência e composição farmacêutica"
WO2009112232A2 (fr) *	2008-03-10	2009-09-17	Vladimir Hanes	Nouveau régime posologique drospirénone/17β-estradiol, produit de combinaison pharmaceutique, et nécessaire pour appliquer ce régime posologique
WO2010042610A1 (fr)	2008-10-08	2010-04-15	Agile Therapeutics, Inc.	Administration transdermique
WO2010042607A1 (fr)	2008-10-08	2010-04-15	Agile Therapeutics, Inc	Administration transdermique
WO2010042612A1 (fr)	2008-10-08	2010-04-15	Agile Therapeutics, Inc.	Délivrance transdermique
EP2410859A4 (fr)	2009-03-27	2013-03-13	Agile Therapeutics Inc	Administration transdermique
WO2016187269A1 (fr) *	2015-05-18	2016-11-24	Agile Therapeutics, Inc.	Compositions contraceptives et procédés d'amélioration de l'efficacité et de modulation d'effets secondaires
EP3272333A1 (fr)	2016-07-22	2018-01-24	Chemo Research, S.L.	Composition vaginale comprenant une combinaison d'oestrogène et de vitamine d

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3669502A (en) †	1971-01-05	1972-06-13	Simpson Timber Co	Pneumatic spreader stoker
US3836651A (en) *	1972-02-22	1974-09-17	Biolog Concepts Inc	Novel oral contraceptive combination
DE2310963A1 (de) †	1972-04-14	1974-09-05	Schering Ag	Methode zur kontrazeption durch verabfolgung von stufenkombinationspraeparaten
DE2365103C3 (de) †	1973-12-21	1980-08-28	Schering Ag, 1000 Berlin Und 4619 Bergkamen	V erwendung von Hormonen zur Kontrazeption
NL8001593A (nl) *	1980-03-18	1981-10-16	Akzo Nv	Meerfasisch combinatiepreparaat voor orale anticonceptie.
US4425339A (en) *	1981-04-09	1984-01-10	Syntex (U.S.A.) Inc.	Treatment of menopausal symptoms
US4826831A (en) *	1983-08-05	1989-05-02	Pre Jay Holdings Limited	Method of hormonal treatment for menopausal or post-menopausal disorders involving continuous administration of progestogens and estrogens
US4544554A (en) *	1983-09-26	1985-10-01	Ortho Pharmaceutical Corporation	Triphasic oral contraceptive
DE3347125A1 (de) *	1983-12-22	1985-07-11	Schering AG, 1000 Berlin und 4709 Bergkamen	Mehrstufenkombinationspraeparat und seine verwendung zur oralen kontrazeption
ZA87332B (en) †	1986-02-27	1987-08-26	Warner Lambert Co	Compositions containing fixed combinations

1987
- 1987-07-08 DK DK198703518A patent/DK174724B1/da not_active IP Right Cessation
- 1987-07-08 IE IE183387A patent/IE61236B1/en active Protection Beyond IP Right Term
- 1987-07-09 ZA ZA875010A patent/ZA875010B/xx unknown
- 1987-07-09 AU AU75379/87A patent/AU597084B2/en not_active Expired
- 1987-07-10 JP JP62504480A patent/JP2645510B2/ja not_active Expired - Lifetime
- 1987-07-10 KR KR1019880700286A patent/KR960001371B1/ko not_active Expired - Lifetime
- 1987-07-10 PT PT85305A patent/PT85305B/pt unknown
- 1987-07-10 PH PH35524A patent/PH25944A/en unknown
- 1987-07-10 WO PCT/US1987/001646 patent/WO1988000469A1/fr not_active Ceased
- 1987-07-13 AT AT87306174T patent/ATE75401T1/de active
- 1987-07-13 EP EP87306174A patent/EP0253607B2/fr not_active Expired - Lifetime
- 1987-07-13 GB GB8716431A patent/GB2192542B/en not_active Expired - Lifetime
- 1987-07-13 ES ES87306174T patent/ES2033850T5/es not_active Expired - Lifetime
- 1987-07-13 DE DE8787306174T patent/DE3778599D1/de not_active Expired - Lifetime
- 1987-07-14 DK DK365887A patent/DK365887D0/da not_active Application Discontinuation
1992
- 1992-04-30 GR GR920400741T patent/GR3004472T3/el unknown
1993
- 1993-04-29 SG SG55093A patent/SG55093G/en unknown
- 1993-07-15 HK HK673/93A patent/HK67393A/xx not_active IP Right Cessation
1994
- 1994-05-06 CY CY172594A patent/CY1725A/en unknown
2000
- 2000-09-06 LU LU90634C patent/LU90634I2/fr unknown
- 2000-11-03 NL NL300025C patent/NL300025I2/nl unknown

Also Published As

Publication number	Publication date
DK174724B1 (da)	2003-10-06
AU7537987A (en)	1988-01-21
EP0253607B2 (fr)	2001-05-23
GB8716431D0 (en)	1987-08-19
LU90634I2 (fr)	2000-12-15
EP0253607B1 (fr)	1992-04-29
KR960001371B1 (ko)	1996-01-26
AU597084B2 (en)	1990-05-24
HK67393A (en)	1993-07-23
PT85305B (pt)	1990-03-30
DE3778599D1 (de)	1992-06-04
DK351887A (da)	1988-01-16
ES2033850T5 (es)	2001-07-01
GR3004472T3 (fr)	1993-03-31
JPH01500431A (ja)	1989-02-16
EP0253607A1 (fr)	1988-01-20
ATE75401T1 (de)	1992-05-15
KR880701553A (ko)	1988-11-03
GB2192542A (en)	1988-01-20
PH25944A (en)	1991-12-19
IE871833L (en)	1988-01-15
DK351887D0 (da)	1987-07-08
NL300025I1 (nl)	2001-01-02
JP2645510B2 (ja)	1997-08-25
ZA875010B (en)	1989-02-22
DK365887D0 (da)	1987-07-14
IE61236B1 (en)	1994-10-19
ES2033850T3 (es)	1993-04-01
WO1988000469A1 (fr)	1988-01-28
PT85305A (en)	1987-08-01
SG55093G (en)	1993-07-09
GB2192542B (en)	1990-05-02
NL300025I2 (nl)	2004-08-02

Publication	Publication Date	Title
EP0253607B2 (fr)	2001-05-23	Forme de dosage combinée pour des femmes pré-ménopausiques
US5276022A (en)	1994-01-04	Hormone preparation and method
AU635270B2 (en)	1993-03-18	Treatment of postmenopausal disorders
US5108995A (en)	1992-04-28	Hormone preparation and method
EP0559240B1 (fr)	2001-12-05	Packages contraceptives contenant de l'estrogen et du progestin
FI110307B (fi)	2002-12-31	Estrogeeni/progestiini/antiprogestiinia sisältävä ehkäisyvalmiste ja pakkaus
US5256421A (en)	1993-10-26	Hormone preparation and method
CZ296387B6 (cs)	2006-03-15	Antikoncepcní prípravek
US3502772A (en)	1970-03-24	Method for stimulating anovulatory cycles and pharmaceutical packages
WO1999025360A2 (fr)	1999-05-27	Regime progestatif-antiprogestatif
Schwartz et al.	1983	Effects of various replacement oestrogens on hepatic transcortin synthesis in climacteric women
CA1332227C (fr)	1994-10-04	Formule de contraceptif oral
DK174181B1 (da)	2002-08-19	Farmaceutisk præparat til hormonbehandling
Haines	1993	Principles of management of the menopause
IE83631B1 (en)		Hormone preparation and method
IE84449B1 (en)	2006-12-13	Contraceptive packages containing oestrogen and progestin